{
	"statements": [
		{
			"id": "moa:69", 
			"description": "T315I mutant ABL1 in p210 BCR-ABL cells resulted in retained high levels of phosphotyrosine at increasing concentrations of inhibitor STI-571, whereas wildtype appropriately received inhibition.", 
			"direction": null, 
			"evidence_level": "moa.evidence_level:Preclinical", 
			"proposition": "proposition:030", 
			"variation_descriptor": "moa:vid69", 
			"therapy_descriptor": "normalize:Imatinib", 
			"disease_descriptor": "normalize:CML", 
			"method": "method:004", 
			"support_evidence": ["support_evidence:016"], 
			"type": "Statement"
		}
	], 
	"propositions": [
		{
			"_id": "proposition:030", 
			"predicate": "predicts_resistance_to", 
			"variation_origin": null, 
			"subject": "ga4gh:VA.wVNOLHSUDotkavwqtSiPW1aWxJln3VMG", 
			"object_qualifier": "ncit:C3174", 
			"object": "ncit:C62035", 
			"type": "therapeutic_response_proposition"
		}
	], 
	"variation_descriptors": [
		{
			"id": "moa:vid69", 
			"type": "VariationDescriptor", 
			"label": "ABL1 p.T315I (Missense)", 
			"description": null, 
			"value_id": "ga4gh:VA.wVNOLHSUDotkavwqtSiPW1aWxJln3VMG", 
			"value": {
				"location": {
					"interval": {
						"end": 315, 
						"start": 314, 
						"type": "SimpleInterval"
					}, 
					"sequence_id": "ga4gh:SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg", 
					"type": "SequenceLocation"
				}, 
				"state": {
					"sequence": "I", 
					"type": "SequenceState"
				}, 
				"type": "Allele"
			}, 
			"xrefs": null, 
			"alternate_labels": null, 
			"extensions": null, 
			"molecule_context": "protein", 
			"structural_type": "SO:0001606", 
			"expressions": null, 
			"ref_allele_seq": "T", 
			"gene_context": "moa:['normalize:ABL1']"
		}
	], 
	"gene_descriptors": [
		{
			"id": "normalize:ABL1", 
			"type": "GeneDescriptor", 
			"label": "ABL1", 
			"description": null, 
			"value_id": null, 
			"value": {
				"gene_id": "hgnc:76", 
				"type": "Gene"
			}, 
			"xrefs": null, 
			"alternate_labels": null, 
			"extensions": null
		}
	], 
	"therapy_descriptors": [
		{
			"id": "normalize:Imatinib", 
			"type": "TherapyDescriptor", 
			"label": "Imatinib", 
			"description": null, 
			"value_id": null, 
			"value": {
				"therapy_id": "ncit:C62035", 
				"type": "Therapy"
			}, 
			"xrefs": null, 
			"alternate_labels": null, 
			"extensions": null
		}
	], 
	"disease_descriptors": [
		{
			"id": "normalize:CML", 
			"type": "DiseaseDescriptor", 
			"label": "Chronic Myelogenous Leukemia", 
			"description": null, 
			"value_id": null, 
			"value": {
				"disease_id": "ncit:C3174", 
				"type": "Disease"
			}, 
			"xrefs": null, 
			"alternate_labels": null, 
			"extensions": null
		}
	], 
	"methods": [
		{
			"id": "method:004", 
			"label": "Clinical interpretation of integrative molecular profiles to guide precision cancer medicine", 
			"url": "https://www.biorxiv.org/content/10.1101/2020.09.22.308833v1", 
			"version": {
				"year": 2020, 
				"month": 9, 
				"day": 22
			}, 
			"reference": "Reardon, B., Moore, N.D., Moore, N. et al."
		}
	], 
	"support_evidence": [
		{
			"id": "support_evidence:016", 
			"support_evidence_id": "pmid:11423618", 
			"label": "Gorre, Mercedes E., et al. \"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.\" Science 293.5531 (2001): 876-880.", 
			"description": null, 
			"xrefs": null
		}
	]
}